ASAH1

ASAH1 Full Name

N-acylsphingosine amidohydrolase (acid ceramidase) 1

ASAH1 Introduction

ASAH1 (N-acylsphingosine amidohydrolase 1), commonly known as acid ceramidase, is a lysosomal enzyme that plays a fundamental role in the metabolism of sphingolipids. The gene encoding ASAH1 is located on human chromosome 8p22 and produces a protein of approximately 395 amino acids that is synthesized as a precursor and subsequently processed into two subunits: an alpha subunit (13 kDa) and a beta subunit (40 kDa), which form a heterodimeric active enzyme. Acid ceramidase catalyzes the hydrolysis of ceramide into sphingosine and free fatty acid, a reaction that is critical for the turnover of ceramide, a central lipid molecule in cellular signaling and metabolism. ASAH1 is ubiquitously expressed in human tissues, with particularly high levels in the liver, spleen, and brain. Dysregulation of ASAH1 has been implicated in several lysosomal storage disorders, neurodegenerative diseases, and cancer, making it an important target for therapeutic intervention.

Figure 1. Strcuture of ASAH1.

Physiological Role in Ceramide Metabolism and Sphingolipid Homeostasis
Ceramide is a central hub in sphingolipid metabolism, acting as a precursor for complex sphingolipids (such as sphingomyelin and glycosphingolipids) and as a substrate for the generation of sphingosine, which is further phosphorylated to sphingosine-1-phosphate (S1P) by sphingosine kinases. The balance between ceramide, sphingosine, and S1P, known as the "sphingolipid rheostat," is critical for regulating cell fate. Ceramide generally promotes cell cycle arrest, apoptosis, and senescence, while S1P promotes cell survival, proliferation, and migration. ASAH1, by converting ceramide to sphingosine, tips this balance away from ceramide and toward S1P. This enzymatic activity is essential for normal cellular homeostasis, as evidenced by the severe consequences of ASAH1 deficiency. In addition to its role in ceramide turnover, ASAH1 also participates in the recycling of sphingolipids in the lysosome, where it degrades ceramide derived from the catabolism of gangliosides and other complex sphingolipids.

ASAH1 in Neurodegenerative Disease
Beyond the rare genetic disorders caused by ASAH1 mutations, accumulating evidence implicates acid ceramidase dysfunction in more common neurodegenerative diseases. In Alzheimer's disease (AD), altered ceramide and sphingolipid metabolism have been observed in the brain, and ASAH1 expression and activity are dysregulated. Elevated ceramide levels in the AD brain may contribute to amyloid-β accumulation, tau hyperphosphorylation, and neuroinflammation. In Parkinson's disease (PD), mutations in other sphingolipid genes (such as GBA1, encoding glucocerebrosidase) are strong risk factors, and ASAH1 may play a modifying role. In multiple sclerosis (MS), ASAH1 activity is altered in immune cells and in the central nervous system, potentially influencing oligodendrocyte survival and myelin integrity. These findings suggest that modulating ASAH1 activity could have therapeutic potential in a range of neurodegenerative conditions.

Alternate Names for ASAH1

ASAH1; N-acylsphingosine amidohydrolase (acid ceramidase) 1; AC; PHP; ASAH; PHP32; ACDase; SMAPME; acid ceramidase; acid CDase; acylsphingosine deacylase; putative 32 kDa heart protein